Prognostic factors other than the performance status and age for glioblastoma multiforme: a single-institution experience

Basit Öğe Kaydı
dc.contributor.authorCaloglu, M.
dc.contributor.authorYurut-Caloglu, V.
dc.contributor.authorKaragol, H.
dc.contributor.authorBayir-Angin, G.
dc.contributor.authorTuran, F. N.
dc.contributor.authorUzal, C.
dc.date.accessioned2024-06-12T10:56:14Z
dc.date.available2024-06-12T10:56:14Z
dc.date.issued2009
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose: To evaluate the survival of patients with glioblastoma multiforme (GBM) and analyse the prognostic Actors influencing survival. Patients and methods: Seventy-eight consecutive patients with GBM treated with radiotherapy (RT) and temozolomide (TMZ) (in 21 patients) between 1999 and 2006 were retrospectively analysed. Results: Sixty-seven (85.5%) patients had undergone gross total or subtotal resection before RT The median overall survival was 9.8 months, and significantly influenced by age (p=0.02), Karnofsky performance status (p=0.001), RT (p<0.0001), gender (p=0.02), concomitant TMZ (p=0.003), RT waiting time (p=0.014), and treatment time (p=0.01) in univariate analysis. In multivariate analysis, older age (p=0.03), male gender (p=0.01), absence of concomitant TMZ (p=0.008), RT dose below 60 Gy (p=0.03), RT waiting time more than 20 days (p=0.01), and treatment time more than 76 days (p=0.0072) were poor prognosticators. Conclusion: This study emphasizes the importance of female gender, dose and duration of RT and RT waiting time in patients with glioblastoma multiforme.en_US
dc.identifier.endpage218en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue2en_US
dc.identifier.pmid19650168en_US
dc.identifier.scopus2-s2.0-67651027830en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage211en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19706
dc.identifier.volume14en_US
dc.identifier.wosWOS:000267610200006en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal Of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChemotherapyen_US
dc.subjectGenderen_US
dc.subjectGlioblastoma Multiformeen_US
dc.subjectPrognostic Factorsen_US
dc.subjectRadiotherapyen_US
dc.subjectSurvivalen_US
dc.subjectGrowth-Factor Receptoren_US
dc.subjectMultivariate-Analysisen_US
dc.subjectAdjuvant Temozolomideen_US
dc.subjectMalignant Gliomasen_US
dc.subjectSurvival-Timeen_US
dc.subjectRadiotherapyen_US
dc.subjectResectionen_US
dc.subjectIrradiationen_US
dc.subjectOncologyen_US
dc.subjectTherapyen_US
dc.titlePrognostic factors other than the performance status and age for glioblastoma multiforme: a single-institution experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu